Life-science investment platform · sponsored by Agile Dynamics
Fund life science from a treasury built to last
AgileBio Tech pairs a rules-based Bitcoin and Treasury-bill certificate, issued in two series, with hands-on venture building. Half of every distribution above the floor buys science-pool units the holders own, with no fixed dividend.
Ways to invest
Choose how you take part
Four routes into the platform, from the treasury fund to co-investing in single assets. Pick one to filter the marketplace.
Marketplace
Investment opportunities
Download each opportunity sheet as a PDF from its card. Sample companies are illustrative archetypes from our strategy, not live deals.
Tickets, timelines and returns marked as placeholders or illustrative are examples, not forecasts. Photos are illustrative.
Operating model
How money moves from treasury to science
One vehicle, two pools with different jobs, and a venture builder that does the hands-on work.
Subscribe
Professional investors buy Growth or Core certificate units through licensed distributors.
Apply the rule
Growth holds 57.1% Bitcoin, Core 20%, the rest in T-bills. Rebalance in up quarters; never sell Bitcoin in a down quarter.
Distribute and route
Pay 0.75–2.5% of NAV each quarter. Half of anything above the floor buys science units the holders own.
Fund science
The Investment Committee approves tranches of US$0.5–2.5M at 5:1; the Scientific Advisory Board verifies milestones.
Revenue shares capped at 2.0× from companies that already sell. Returns go to unit holders, never into the treasury.
The link routes only upside above the floor, never capital, and holders can opt out to cash.
Agile Dynamics runs regulatory, business development, launch and finance services for every portfolio company.
Deal intelligence for the science pool
Which asset, which country, which deal, and what it’s really worth
OpportunityIQ is the AI business-intelligence platform Agile Dynamics is building for the AgileBio Tech ecosystem. It turns evidence from health authorities, regulators, trial registries, patent offices and licensed market data into a ranked pipeline of opportunities, each with the same auditable business case.
- 01Sizes the demand. Patient-flow funnels from total to obtainable market, year by year.
- 02Values each deal. Owner receipts, rNPV, IRR and peak funding for every route to market.
- 03Gates every call. Expert sign-off before an opportunity reaches the Investment Committee.

Structure and jurisdictions
Swiss certificate. Guernsey issuer. Hong Kong sponsor.
Each job sits in the jurisdiction built for it: a Swiss-law certificate, an independent Guernsey issuer, and a Hong Kong sponsor seat that reaches professional investors through licensed intermediaries.
Summary only; terms are indicative and subject to counsel’s opinions in three jurisdictions.
Swiss-law actively managed certificate with a CH ISIN; FINMA-supervised manager and custodian; settled through SIX SIS.
Incorporated cells with GFSC consent, an independent board majority and orphan ownership.
Sponsor seat; professional investors reached only through licensed intermediaries.
Five sanctions lists checked at every step, with a ring-fence on both pools.
No offer, marketing, accounts or custody on the mainland, in line with PBOC Notice No. 42.
Governance
The people who pick deals do not hold or value the money
The sponsor sponsors; it does not control. It gives no advice, places no orders and holds no assets.
Independent majority and orphan ownership; approves every related-party matter.
A FINMA-supervised manager executes the written rule, with no discretion on payouts.
Tests every trade against the rule and computes each payout and the science link.
The Investment Committee approves tranches; the Scientific Advisory Board verifies milestones.
Roadmap
Raise from January to June 2027
If a gate’s conditions are not met, the date moves and the conditions do not.
Legal setup
Counsel’s opinions in Switzerland, Guernsey and Hong Kong; Latin American tax advisers briefed.
Providers and soft circle
Binding cost quotes, providers, a named CIO and CFO, then a soft circle of US$25M or more with two Latin American targets.
First close
US$50M binding across the Growth and Core series; fixed costs capped at US$0.5M a year.
Science pool
First vintage of US$4–5M in Latin America: tranches of US$0.5–2.5M at 5:1, revenue shares capped at 2.0×.
Get in touch
Start a conversation
Tell us whether you are an investor, a scientific partner or a growth company. We offer a 90-minute working session on structure, governance and the first deals.
